ABBOTT PARK, Ill., August 4, 2025 – Global healthcare leader Abbott Laboratories (NYSE: ABT) closed the trading day on Friday, August 1, at $127.29, marking a flat end to a session characterized by moderate volatility. The stock’s steady performance, navigating a tight range between a low near $125.50 and a high of approximately $127.80, reflects a confident market digesting a strong second-quarter earnings report. Investors are balancing the company’s powerful growth in its Medical Devices segment against persistent challenges in diagnostics, ultimately affirming a positive outlook on the diversified healthcare giant.
The stock is currently positioned comfortably between its 52-week high of $141.23 and low of $107.10, backed by a solid price-to-earnings ratio of 15.89 and a reliable dividend. This stability is a testament to Abbott’s successful strategy of leveraging its diverse portfolio to deliver consistent growth, even as the tailwinds from the COVID-19 pandemic have subsided.
A Tale of Two Segments: MedTech Soars While Diagnostics Normalize
Abbott’s recent financial results paint a clear picture of its current operational landscape. The company reported impressive second-quarter 2025 results, with total revenue climbing 7.4% to $11.14 billion and adjusted earnings per share showing double-digit growth to $1.26, meeting analyst expectations. This robust performance, however, reveals a strategic shift in the company’s growth drivers.
The undisputed star of the show is the Medical Devices division, which has become the company’s largest business, accounting for 45% of total revenue. This segment delivered powerful double-digit organic sales growth for the eighth consecutive quarter, with sales surging 13.4% to $5.37 billion in the second quarter. This exceptional performance was driven by a portfolio of innovative products that are capturing significant market share.
Leading the charge is the FreeStyle Libre continuous glucose monitoring (CGM) system. This revolutionary device for diabetes management continues its remarkable trajectory, with sales reaching $1.9 billion in the second quarter, a 21.4% increase. The Libre franchise is now on a path to achieving its ambitious goal of $10 billion in annual sales by 2028, propelled by expanding reimbursement and its
